Nanoscope Therapeutics Announces Participation in Upcoming Conferences

Nanoscope Therapeutics Announces Participation in Upcoming Conferences

DALLAS, Feb. 21, 2024 /PRNewswire/ — Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced that Sulagna Bhattacharya, Chief Executive Officer of Nanoscope Therapeutics, and other members of its senior management team will participate in two upcoming conferences. Details are as follows:

BIO CEO & Investor Conference

Session Date: Monday, February 26, 2024
Session Time: 4:45 – 4:58 p.m. ET
Location: NY Marriott Marquis
Presenter: Sulagna Bhattacharya, Chief Executive Officer

Ms. Bhattacharya presently serves on the board of directors of BIO. In her presentation, she will give an overview of Nanoscope’s Multi-Characteristic Opsin platform and highlight the Company’s gene-agnostic approach. Nanoscope leadership will also be available for meetings during the conference.

Evercore ISI 2024 Emerging Private Biotech Conference

Session Date: Wednesday, February 28, 2024
Session Time: 1:40 – 2:10 p.m. ET
Presenter: Sulagna Bhattacharya, Chief Executive Officer

In the fireside chat, Ms. Bhattacharya will discuss Nanoscope’s Multi-Characteristic Opsin platform as well as recent clinical data from the clinical trials for patients with advanced retinitis pigmentosa and Stargardt disease. Nanoscope leadership will also be available for 1×1 meetings for the duration of the conference.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by inherited retinal diseases for which no cure exists. The company’s lead asset, MCO-010, recently reported topline results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also recently completed the Phase 2 STARLIGHT trial of MCO-010 therapy in patients with Stargardt disease (NCT05417126). MCO-010 has received FDA fast track designations and FDA orphan drug designations for both retinitis pigmentosa and Stargardt. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
212-600-1902
[email protected]

SOURCE Nanoscope Therapeutics

On February 21, 2024   /   Nanoscope Press Release, Home Page  
Nanoscope Therapeutics, Inc.
Trinity Towers
2777 N. Stemmons Fwy.
Dallas, TX 75207
(817) 857-1186

  • Dr. Samarendra Mohanty, PhD |  Co-Founder & President

    Samarendra Mohanty (Co-Founder/President) is an inventor & serial entrepreneur with 20+ years experience in Biomedical Sciences. He is Co-Founder of several Biotechs and Biomedical device /diagnostic companies (developed & commercialized $100K+ biomedical instruments.)

    Dr. Mohanty obtained M.Tech in Applied Optics from the Indian Institute of Technology-Delhi and a PhD in (Bio)Physics from the Indian Institute of Sciences-Bangalore.

    His extensive Biomedical Technologies experience includes serving as Professor/Senior Scientist at the University of Texas;  University of California, Irvine; Center for Adv. Tech (India); Int. Mol. Biotech (Germany); Univ. Pavia (Italy); NUS (Singapore); and University of St. Andrews (UK). He has authored over 200 international patents and publications in leading journals including Nature and Nature Photonics.

    He is the Principal Investigator for major grants from the National Eye Institute including Audacious Goal Initiative and Bioengineering Research grants. He serves on the editorial board of journals and chairs an international conference on optogenetics. He is the winner of a 2019 Healthcare Heroes award (Fort Worth Business Press), Retinal Organoid Challenge Award, Audacious Goal Initiative Award (NIH), Finalist of Tech Titan, and NIH-Director’s Innovator Award.